Cilomilast, a second generation phosphodiestease 4 inhibitor, in combination with PGE2 attenuates fMLP, IL-8 and cigarette smoke-induced effects on the mechanical and functional properties of neutrophils Source: Eur Respir J 2001; 18: Suppl. 33, 161s Year: 2001
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
Inhibition of mast cell PGD2 release protects against mannitol-induced airway narrowing Source: Eur Respir J 2006; 27: 944-950 Year: 2006
Phosphodiesterase 4 inhibition of β2-integrin adhesion caused by leukotriene B4 and TNF-α in human neutrophils Source: Eur Respir J 2006; 28: 920-928 Year: 2006
Liver-X-receptor agonists, but not dexamethasone, inhibit leukotriene production from human white blood cells pretreated with GM-CSF and activated with fMLP Source: Annual Congress 2007 - New treatments for asthma and COPD - experimental evidence Year: 2007
Evidence of mast cell activation and leukotriene release after mannitol inhalation Source: Eur Respir J 2003; 22: 491-496 Year: 2003
The effects of a cysteinyl leukotriene receptor antagonist, pranlukast, on dendritic cell chemoattractants in the airways of subjects with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Effects of N-acetylcysteine and salbutamol on neutrophil migration and release of interleukin-8 and elastase by neutrophils in vitro Source: Eur Respir J 2004; 24: Suppl. 48, 579s Year: 2004
Quantitative assessment of cysteinyl leukotrienes in human sputum during the allergen-induced asthmatic response and the effect of GSK2190915, a 5-lipoxygenase activating protein (FLAP) inhibitor Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011
A leukotriene antagonist, montelukast, reduces in vitro LTD4 increases in peripheral blood eosinophil progenitor colonies in atopic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 531s Year: 2001
Differential actions of phosphatidyinositol 3-kinase inhibitors on respiratory burst and leukotriene C4 generation in PAF-stimulated human eosinophils Source: Eur Respir J 2003; 22: Suppl. 45, 547s Year: 2003
Production of leukotriene C4 by peripheral blood leukocytes stimulated with anti-IgERI antibody, PMA, and fMLP do not correlate with the degree of irreversible bronchoobturation in asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 354s Year: 2004
Synergistic inhibition of salmeterol with fluticasone propionate or rolipram on stimulated eosinophil binding of β2 -integrin to ICAM-1 and cytosolic gIV-phospholipase A2 activation Source: Eur Respir J 2003; 22: Suppl. 45, 455s Year: 2003
The pro-apoptotic effect of cysteinyl leukotriene receptor (CysLT-R) antagonist montelukast is mediated by CysLT-Rs expression on antigen-stimulated T cells Source: Eur Respir J 2003; 22: Suppl. 45, 100s Year: 2003
Intranasal administration of leukotriene B4 selectively increases human nasal neutrophil activity Source: Annual Congress 2008 - Phenotyping of asthma and COPD Year: 2008
Leukotriene B4 release by human lung macrophages via receptor- not voltage-operated Ca2+ channels Source: Eur Respir J 2009; 33: 1105-1112 Year: 2009
Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo Source: Eur Respir J 2003; 21: 994-999 Year: 2003
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
Effect of piclamilast, a selective phosphodiesterase (IV)-inhibitor, theophylline and prednisolone, on sputum cell and blood neutrophil oxidative burst from mild asthmatics Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003
Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 20s Year: 2004